Mass balance analysis of contaminated heparin product

Analytical Biochemistry

Volumn 408, Issue 1, 2011, Pages 147-156

  Liu, Zhenling ^a,b   Xiao, Zhongping ^b   Masuko, Sayaka ^b   Zhao, Wenjing ^c   Sterner, Eric ^d   Bansal, Vinod ^e   Fareed, Jawed ^e   Dordick, Jonathan ^c,d   Zhang, Fuming ^d   Linhardt Robert J , R J ^b,c,d  

^a LANZHOU UNIVERSITY   (China)

^b Rensselaer Polytechnic Institute   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Contaminant; Dermatan sulfate; Glycosaminoglycan; Heparin; Heparin lyases; Mass balance analysis; OSCS; Oversulfated chondroitin sulfate

Indexed keywords

BIOASSAY; DRUG PRODUCTS; ENZYMES; IMPURITIES; POLYSACCHARIDES; SODIUM CHLORIDE; SULFUR COMPOUNDS;

CHONDROITIN SULFATES; DERMATAN SULFATE; GLYCOSAMINOGLYCANS; HEPARIN; HEPARIN LYASES; MASS BALANCE ANALYSIS; OSCS;

CONTAMINATION;

BENZYL ALCOHOL; CHONDROITIN; DERMATAN SULFATE DERIVATIVE; EXCIPIENT; HEPARIN; LYASE; SODIUM CHLORIDE;

ARTICLE; DRY MASS; ENZYME ANALYSIS; ENZYME SPECIFICITY; FREEZE DRYING; GLACIAL MASS BALANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 77958474965     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.09.015     Document Type: Article

References (46)

1. Linhardt R.J. 2003 Claude S. Hudson Award address in carbohydrate chemistry: Heparin-Structure and activity. J. Med. Chem. 2003, 46:2551-2554.
2. Munoz E.M., Linhardt R.J. Heparin binding domains in vascular biology. Arterioscl. Thromb. Vasc. 2004, 24:1549-1557.
3. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009, 26:313-321.
4. Casu B. Heparin structure. Haemostasis 1990, 20:62-73.
5. Gunay N.S., Linhardt R.J. Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 1999, 25:5-16.
6. Linhardt R.J., Loganathan D. Biomimetic polymers. Heparin, Heparinoids, and Heparin Oligosaccharides: Structure and Biological Activities 1990, 135-173. Plenum, New York. G. Gebelein (Ed.).
7. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
8. 1H NMR and PAGE. J. Pharm. Sci. 2009, 98:4017-4026.
9. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
10. Guerrini M., Zhang Z., Shriver Z., Naggi A., Masuko S., Langer R., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc. Natl. Acad. Sci. USA 2009, 106:16956-16961.
11. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
12. Blossom D.B., Kallen J.A., Patel P.R., Elward A., Robinson L., Gao G., Langer R., Perkins K.M., Jaeger J.L., Kurkjian K.M., Jones M., Schillie S.F., Shehab N., Ketterer D., Venkataraman G., Kishimoto T.K., Shriver Z., McMahon A.W., Austen K.F., Kozlowski S., Srinivasan A., Turabelidze G., Gould C.V., Arduino M.J., Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008, 359:2674-2684.
13. Adam A., Montpas N., Keire D., Désormeaux A., Brown N.J., Marceau F., Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 22:5741-5748.
14. Li B., Suwan J., Martin J.G., Zhang F., Zhang Z., Hoppensteadt D., Clark M., Fareed J., Linhardt R.J. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem. Pharmacol. 2009, 78:292-300.
15. Carranza Y.E., Durand-Rougley C., Doctor V. Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate. Blood Coagul. Fibrinolysis. 2008, 6:483-487.
16. Pan J., Qian Y., Zhou X., Pazandak A., Frazier S.B., Weiser P., Lu H., Zhang L. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat. Biotechnol. 2010, 28:203-207.
17. U.S. Food and Drug Administration, Information on heparin, http://www.fda.gov/cder/drug/infopage/heparin/default.htm.
18. Zhang Z., Weïwer M., Li B., Kemp M.M., Daman T.H., Linhardt R.J. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low molecular weight heparin preparation. J. Med. Chem. 2008, 51:5498-5501.
19. U.S. Pharmacopeia, USP heparin information, http://www.usp.org/hottopics/heparin.html.
20. Spencer J.A., Kauffman J.F., Reepmeyer J.C., Gryniewicz C.M., Ye W., Toler D.Y., Buhse L.F., Westenberger B.J. Screening of heparin API by near infrared reflectance and Raman spectroscopy. J. Pharm. Sci. 2009, 98:3540-3547.
21. Trehy M.L., Reepmeyer J.C., Kolinski R.E., Westenberger B.J., Buhse L.F. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J. Pharm. Biomed. Anal. 2009, 49:670-673.
22. Limtiaco J.F.K., Jones C.J., Larive C.K. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography. Anal. Chem. 2009, 81:10116-10123.
23. 1H NMR, SAX-HPLC, and anticoagulation time approaches. J. Pharm. Biomed. Anal. 2010, 52:656-664.
24. 1H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by oversulfated chondroitin sulfate. J. Pharm. Biomed. Anal. 2010, 51:921-926.
25. Hashii N., Kawasaki N., Itoh S., Qin Y., Fujita N., Hattori T., Miyata K., Bando A., Sekimoto Y., Hama T., Kashimura M., Tatsumi M., Mabuchi K., Namekawa H., Sakai T., Hirose M., Dobashi S., Shimahashi H., Koyama S., Herr S.O., Kawai K., Yoden H., Yamaguchi T. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography. Biologicals 2010, 38:539-543.
26. Volpi N., Maccari F., Linhardt R.J. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal. Biochem. 2009, 388:140-145.
27. Kakoi N., Kinoshita M., Kawasaki N., Yamaguchi T., Hayakawa T., Kakehi K., Yakugaku Z. Capillary electrophoresis analysis of contaminants in heparin sodium for the Japanese pharmacopeia purity test. Yakugaku Zasshi 2009, 129:1255-1264.
28. Wielgos T., Havel K., Ivanova N., Weinberger R. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers. J. Pharm. Biomed. Anal. 2009, 49:319-326.
29. Domanig R., Jöbstl W., Gruber S., Freudemann T. One-dimensional cellulose acetate plate electrophoresis: a feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin. J. Pharm. Biomed. Anal. 2009, 49:151-155.
30. Somsen G.W., Tak Y.H., Toraño J.S., Jongen P.M., de Jong G.J. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis. J. Chromatogr. A 2009, 1216:4107-4112.
31. Bairstow S., McKee J., Nordhaus M., Johnson R. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Anal. Biochem. 2009, 388:317-321.
32. 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2008, 48:13-19.
33. Sitkowski J., Bednarek E., Bocian W., Kozerski L. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractionated heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J. Med. Chem. 2008, 51:7663-7665.
34. 1H NMR spectroscopy. J. Pharm. Biomed. Anal. 2009, 49:1060-1064.
35. S. Lühn, S. Schiemann, S. Alban, Simple fluorescence assay for quantification of OSCS in heparin, Anal. Bioanal. Chem. in press, doi:10.1007/s00216-010-3867-5.
36. Wang L., Buchanan S., Meyerhoff M.E. Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal. Chem. 2008, 80:9845-9847.
37. Linhardt R.J. Analysis of glycosaminoglycans with polysaccharide lyases. Curr. Protoc. Mol. Biol. 1999, 17.13B.1-17.13B.16.
38. Guerrini M., Shriver Z., Naggi A., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is the major contaminant in suspect heparin lots collected in February/March of 2008. Nat. Biotechnol. 2010, 28:207-211.
39. Pan J., Qian Y., Zhou X., Pazandak A., Frazier S.B., Weiser P., Lu H., Zhang L. Identification of chemically sulfated/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin. Glycobiol. Insights 2010, 2:1-12.
40. Beyer T., Matz M., Brinz D., Rädler O., Wolf B., Norwig J., Baumann K., Alban S., Holzgrabe U. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. Eur. J. Pharm. Sci. 2010, 40:297-304.
41. Zhang Z., McCallum S.A., Xie J., Nieto L., Corzana F., Jimenez-Barbero J., Chen M., Liu J., Linhardt R.J. Solution structures of chemoenzymatically synthesized heparin and its precursors. J. Am. Chem. Soc. 2008, 130:12998-13007.
42. Edens R.E., Al-Hakim A., Weiler J.M., Rethwisch D.G., Fareed J., Linhardt R.J. Gradient polyacrylamide gel electrophoresis for determination of the molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J. Pharm. Sci. 1992, 81:823-827.
43. Zhang Z., Xie J., Liu H., Liu J., Linhardt R.J. Quantification of heparan sulfate and heparin disaccharides using ion-pairing, reverse-phase, micro-flow, high performance liquid chromatography coupled with electrospray ionization trap mass spectrometry. Anal Chem. 2009, 81:4349-4355.
44. Willhite T.B., Sawochka S.G., Pearl W.L. Quantification of sodium, chloride, and sulfate transport in power-generating systems. American Society for Testing and Materials (ASTM) special technical publication 1981, 742:83-91.
45. Clark M., Hoppensteadt D., Walenga J., Myers L., Cunanan J., Jeske W., Adiguzel C., Iqbal O., Fareed J. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins: comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Intl. Angiol. 2008, 27:370-376.
46. Yamagata T., Saito H., Habuchi O., Suzuki S. Purification and properties of bacterial chondroitinases and chondrosulfatases. J. Biol. Chem. 1968, 243:1523-1535.